<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To determine if the combination of <z:chebi fb="0" ids="9753">troglitazone</z:chebi> (a peroxisome proliferator-activated receptor-gamma activator) and <z:chebi fb="0" ids="26831">sulfonylurea</z:chebi> will provide efficacy not attainable by either medication alone </plain></SENT>
<SENT sid="1" pm="."><plain>RESEARCH DESIGN AND METHODS: There were 552 patients inadequately controlled on maximum doses of <z:chebi fb="0" ids="26831">sulfonylurea</z:chebi> who participated in a 52-week randomized active-controlled multicenter study </plain></SENT>
<SENT sid="2" pm="."><plain>Patients were randomized to micronized <z:chebi fb="0" ids="5441">glyburide</z:chebi> 12 mg q.d </plain></SENT>
<SENT sid="3" pm="."><plain>(G12); <z:chebi fb="0" ids="9753">troglitazone</z:chebi> monotherapy 200, 400, or 600 mg q.d </plain></SENT>
<SENT sid="4" pm="."><plain>(T200, T400, T600); or combined <z:chebi fb="0" ids="9753">troglitazone</z:chebi> and <z:chebi fb="0" ids="5441">glyburide</z:chebi> q.d </plain></SENT>
<SENT sid="5" pm="."><plain>(T200/G12, T400/G12, T600/G12) </plain></SENT>
<SENT sid="6" pm="."><plain>Efficacy measures included HbA1c, fasting serum <z:chebi fb="105" ids="17234">glucose</z:chebi> (FSG), insulin, and C-<z:chebi fb="7" ids="16670">peptide</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>Effects on <z:chebi fb="23" ids="18059">lipids</z:chebi> and safety were also assessed </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: Patients on T600/G12 had significantly lower mean (+/- <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SEM</z:e>) FSG (9.3 +/- 0.4 mmol/l; 167.4 +/- 6.6 mg/dl) compared with control subjects (13.7 +/- 0.4 mmol/l; 246.5 +/- 6.8 mg/dl; P &lt; 0.0001) and significantly lower mean HbA1c (7.79 +/- 0.2 vs. 10.58 +/- 0.18%, P &lt; 0.0001) </plain></SENT>
<SENT sid="9" pm="."><plain>Significant dose-related decreases were also seen with T200/G12 and T400/G12 </plain></SENT>
<SENT sid="10" pm="."><plain>Among patients on T600/G12, 60% achieved HbA1c &lt; or =8%, 42% achieved HbA1c &lt; or =7%, and 40% achieved FSG &lt; or =7.8 mmol/l (140 mg/dl) </plain></SENT>
<SENT sid="11" pm="."><plain>Fasting insulin and C-<z:chebi fb="7" ids="16670">peptide</z:chebi> decreased with <z:hpo ids='HP_0000001'>all</z:hpo> treatments </plain></SENT>
<SENT sid="12" pm="."><plain>Overall, <z:chebi fb="4" ids="17855">triglycerides</z:chebi> and free fatty acids decreased, whereas <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> increased </plain></SENT>
<SENT sid="13" pm="."><plain><z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi> increased slightly, with no change in <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> B </plain></SENT>
<SENT sid="14" pm="."><plain>Adverse events were similar across treatments </plain></SENT>
<SENT sid="15" pm="."><plain><z:hpo ids='HP_0001943'>Hypoglycemia</z:hpo> occurred in 3% of T600/G 12 patients compared with &lt;1% on G12 or <z:chebi fb="0" ids="9753">troglitazone</z:chebi> monotherapy CONCLUSIONS: Patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> inadequately controlled on <z:chebi fb="0" ids="26831">sulfonylurea</z:chebi> can be effectively managed with a combination of <z:chebi fb="0" ids="9753">troglitazone</z:chebi> and <z:chebi fb="0" ids="26831">sulfonylurea</z:chebi> that is safe, well tolerated, and represents a new approach to achieving the glycemic targets recommended by the American <z:mp ids='MP_0002055'>Diabetes</z:mp> Association </plain></SENT>
</text></document>